Magic mushroom drug tested to lift depression in Alzheimer's patients
NCT ID NCT04123314
Summary
This small, early-stage study from Johns Hopkins University is testing whether the psychedelic compound psilocybin, given in a controlled setting with support, can safely reduce depression in people with mild cognitive impairment or early Alzheimer's disease. Up to 20 participants will receive two guided psilocybin sessions over 8 weeks. The main goal is to see if it improves their mood and quality of life, with follow-up checks for six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Center for Psychedelic and Consciousness Research
RECRUITINGBaltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.